Recent advances in genome editing technologies have magnified the prospect of single-
dose cures for many genetic diseases. For most genetic disorders, precise DNA correction is …

Since its mechanism discovery in 2012 and the first application for mammalian genome
editing in 2013, CRISPR-Cas9 has revolutionized the genome engineering field and created …

Most known pathogenic point mutations in humans are C• G to T• A substitutions, which can
be directly repaired by adenine base editors (ABEs). In this study, we investigated the …

Dyslipidemia, characterized by a high level of lipids (cholesterol, triglycerides, or both), can
increase the risk of developing and progressing atherosclerosis. As atherosclerosis …

The clinical benefit of lipid-lowering therapies is to reduce circulating levels of atherogenic
particles and to ameliorate the risk of atherosclerotic cardiovascular disease (ASCVD). The …

Base editing is a powerful CRISPR-based technology for introducing precise substitutions
into the genome. This technology greatly advances mutagenesis possibilities in vivo …

When secreted into the circulation, proprotein convertase subtilisin kexin type 9 (PCSK9)
blocks the low-density lipoprotein receptors (LDL-R) and, as a consequence, low-density …

The steady progress in genome editing, especially genome editing based on the use of
clustered regularly interspaced short palindromic repeats (CRISPR) and programmable …

Abstract Streptococcus pyogenes Cas9 (SpCas9) and derived enzymes are widely used as
genome editors, but their promiscuous nuclease activity often induces undesired mutations …

Atherosclerosis is a multifactorial disease influenced by genetics, lifestyle and
environmental factors. Despite therapeutic advances that reduce the risk of cardiovascular …